Offering's proceeds for phase 1 clinical development of EPZ-5676
By Devika Patel
Knoxville, Tenn., May 31 - Epizyme, Inc. priced its $77.13 million initial public offering of stock with an $11.57 million greenshoe in a prospectus filed Friday with the Securities and Exchange Commission. It expects the shares to trade on the Nasdaq under the symbol "EPZM."
The deal was announced on April 18.
The company will sell 5,142,000 common shares at $15.00 apiece.
Citigroup, Cowen and Co., Leerink Swann, JMP Securities and Wedbush PacGrow Life Sciences are assisting.
Settlement is expected on June 5.
Proceeds will be used for phase 1 clinical development of EPZ-5676, development costs, research and development and working capital and general corporate purposes.
The biopharmaceutical company is based in Cambridge, Mass.
| Issuer: | Epizyme, Inc.
|
| Issue: | Common stock
|
| Amount: | $77.13 million
|
| Greenshoe: | $11,569,500
|
| Shares: | 5,142,000
|
| Price: | $15.00
|
| Warrants: | No
|
| Announcement date: | April 18
|
| Pricing date: | May 31
|
| Settlement date: | June 5
|
| Stock exchange: | Nasdaq: EPZM
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
